[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-tumours\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-tumours":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100627190","italian-group-of-regenerative-and-occlusive-worldwide-used-techniques-of-hepatic-hypertrophy-100627190",false,"NCT07445412","Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy","Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy - IGROWtoh","I-GROWtoh","Inclusion Criteria:\n\n* Patients aged 18 or older\n* Obtaining informed consent\n* Patients with liver neoplasia (benign or malignant) and with a future liver remnant volume deemed insufficient (\\\u003C20%-40%) by the local multidisciplinary team\n\nExclusion Criteria:\n\n* pregnant or breastfeeding woman","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy. Patients will be treated according to the current clinical practice of the participating centers and will be observed from the moment of recruitment and throughout their stay. Information on vital status will be collected, as far as possible, for up to 5 years after surgery in order to record any events that occur in a timely manner. There are also plans to retrospectively collect data on patients who underwent hypertrophic techniques in the previous 10 years, in order to establish a historical cohort for each center that can be used for comparison with the prospective cohort.",[26,27,28,29],"Liver Tumours","Liver Cancer (Primary and Metastatic)","Liver Resection","Liver Hypertrophy","RECRUITING","2026-02-25",{"date":33,"type":34},"2026-03-03","ACTUAL",{"date":36,"type":34},"2024-10-22",{"date":38,"type":21},"2040-04",{"name":40,"class":41},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100603927","evaluation-of-liver-resection-using-harmonic-scalpel-versus-cavitron-ultrasonic-surgical-aspirator-cusa-100603927","NCT07142876","Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA).","Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA)","Inclusion Criteria:\n\n* patients needing liver resection in normal liver and cirrhotic liver child-pough A and early B\n* Age \\> 6 and \\\u003C 70 years old\n* One or two small (5 cm or less) hepatic lesions confined to the liver with no extra hepatic involvement\n* Patients with -ve markers for viral hepatitis\n\nExclusion Criteria:\n\n* patients with age \\\u003C 6 or \\> 70 years old\n* liver cirrhosis Child-pough C\n* liver cell failure\n* very large lesions including most of the liver tissue\n* hepatic lesions with vascular invasion\n* evidence of metastasis in cases with HCC\n* patients with +ve markers for viral hepatitis","6 Years","70 Years",{"count":53,"type":21},50,"INTERVENTIONAL",[56],"NA","Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA)\n\nIntroduction The mode of parenchymal transection in hepatic resection has been a topic of great debate for decades. Many resections have now evolved into laparoscopic , and robotic-assisted procedures to limit morbidity. Morbidity and mortality after hepatic resection has progressively improved over the years due to improved equipment, operative technique \\[3\\], and anesthetic management. Prior to 1980, mortality rates were reported to be in the 10-20% range with many deaths related to perioperative hemorrhage. Now perioperative mortality has dropped significantly to approximately 5%.\n\nThe clamp-crush technique, first reported in 1974, has been used for decades and remains the standard means of parenchymal division for many surgeons. Control of intraoperative hemorrhage has been one of the principle technical problems in advancing liver surgery. Excess blood loss and intraoperative blood transfusions have been shown to be associated with increased perioperative mortality and morbidity including an increased rate of hepatocellular carcinoma recurrence . Transfusions are also associated with increased infections and with increased cost. Costs of blood transfusions were recently examined in surgical patients.\n\nMany devices are now available to surgeons for division of the liver parenchyma in both open and minimally invasive surgery including: the CUSA (Tyco Healthcare, Mansfield, MA), Harmonic Scalpel (Ethicon Endo-Surgery, Cincinnati, OH, USA), Ligasure (Valley Lab, Tyco Healthcare, Boulder, CO, USA), Tissue Link (Salient Surgical Technologies, Portsmouth, NH), water-jet dissection, radiofrequency, microwave assisted resection, vascular staplers, and others In this study, we looked at the TissueLink bipolar sealer device that was used in combination with the CUSA in group 1 termed the CUSA\u002FTissueLink group, and the Harmonic Scalpel in the group 2 termed Harmonic Scalpel\u002FTissueLink. The TissueLink uses radiofrequency energy focused near the end of the device for electrocautery and a low volume saline drip that produces ohmic heat causing precoagulation of hepatic parenchyma. The saline keeps the temperature at or below 100 C to avoid eshcar formation ultimately helping prevent delayed biliary leak and hemorrhage. The hemostatic effects of TissueLink are a result of its disruption of the collagen in blood vessels causing closing of the lumen .\n\nThe CUSA, a commonly used device in hepatic resection, was used in combination with the TissueLink in this study. We previously described this combination of devices reporting a shorter length of hospital stay, decreased operative time, and decreased intraoperative blood transfusion . CUSA uses ultrasonic energy to fragment and aspirate parenchymal tissue. This exposes biliary as well as vascular structures that may then be closed in a variety of ways at the surgeon's discretion. It allows for a precise transection plane allowing preservation of normal hepatic tissue .\n\nThe Harmonic Scalpel, used in this study in combination with the TissueLink, utilizes ultrasonic vibration of two blades causing destruction of hydrogen bonds. This disruption of hydrogen bonds causes protein denaturization coagulating small vessels of 3 mm diameter. The parenchyma is also cut when the blades move in a saw-like fashion In this study, we evaluated the safety and efficacy of two different techniques described above for the division of the hepatic parenchyma in order to improve perioperative outcomes.",[28,26,59,60],"Liver Transplant Disorder","Trauma Abdomen",[62,63,64,65],"liver resection","CUSA","Cavitron Ultrasonic Surgical Aspirator","Harmonic","NOT_YET_RECRUITING","2025-08-26",{"date":69,"type":34},"2025-08-27",{"date":71,"type":21},"2025-08-22",{"date":73,"type":21},"2026-12-30",{"name":75,"class":41},"Sohag University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":42},"100586381","immunotherapy-care-and-prevention-of-infectious-and-tumoral-diseases-immunohub-100586381","NCT06914635","Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)","Inclusion Criteria:\n\nLine 1: - Age \\>18 at time of signing informed consent form\n\n* Signed informed consent form Line 2: - Primery liver tumor\n* Age \\>18 at time of signing informed consent form\n* Signed informed consent form\n\nExclusion Criteria:\n\nLine 1: - Active or history of neoplastic malignancy\n\n* Active autoimmune disease ongoing treatment with immunosuppressive therapy\n* Evidence of positive HIV, HCV, HBV test\n* Diabetes\n* Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months\n* Chronic autoimmune or inflammatory diseases\n* Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies\n* Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \\>3 years prior to signing informed consent and considered low risk of relapse\n* HIV infection\n* Failure to sign informed consent form",true,"90 Years",{"count":85,"type":21},40,"The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.",[88,26],"SARS CoV-2","2025-03-31",{"date":91,"type":34},"2025-04-06",{"date":93,"type":34},"2023-05-30",{"date":95,"type":21},"2027-02",{"name":97,"class":41},"Fondazione IRCCS Policlinico San Matteo di Pavia"]